SPOTLIGHT -
EP. 1: Case Study: Treating an Elderly Patient With Squamous NSCLC
EP. 2: Case Study: Maintenance Therapy in Squamous NSCLC
EP. 3: Case Study: Mutation-Negative Patient With Adenocarcinoma
EP. 4: PRONOUNCE Trial: Two Drug Versus Three Drug Regimens
EP. 5: Case Study: Second-Line Treatment of Adenocarcinoma
EP. 6: Case Study: MET and ALK Targeted Therapies in NSCLC
EP. 7: Case Study: Progression on ALK Inhibitors in NSCLC
EP. 8: Case Study: Treating KRAS-Mutant Adenocarcinoma
EP. 9: Targeting the Immune System in Non-Small Cell Lung Cancer
EP. 10: Novel Immunotherapy Combinations in NSCLC
EP. 11: GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC
EP. 12: Selecting a First-Line EGFR Inhibitor in NSCLC
EP. 13: Conclusion: Final Thoughts on Treatment Advances in NSCLC
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC